Prevalence of SARS-CoV-2 Antibodies in Hemodialysis Patients in Senegal: A Multicenter Cross-Sectional Study

Sidy Mohamed Seck (✉ sidy-mohamed.seck@ugb.edu.sn)  
University Gaston Berger  
Moustapha Mbow  
University Cheikh Anta Diop  
Yaya Kane  
University Assane Seck  
Mouhamadou Moustapha Cisse  
Université de Thiès  
Gnagna Faye  
HOGIP  
Adama Kama  
CHR EIN Kaolack  
Moussa Sarr  
CHR Louga, Senegal  
Pamela Nitcheu  
CHR Tamba  
Mohamed Dahaba  
CHN Fawzeyni  
Ibrahima Mbemba Diallo  
University Gaston Berger  
Mame Selly Diawara  
Université de Thiès  
Lotingo Nehemie Motoula Latou  
Dialysis Center, Military Hospital of Ouakam  
Yacine Dia  
Institute of Health Research, Epidemiological Surveillance and Training  
Souleymane Mboup  
Institute of Health Research, Epidemiological Surveillance and Training  

Research Article
Keywords: SARS-CoV-2, COVID-19, Seroprevalence, Hemodialysis, Senegal

DOI: https://doi.org/10.21203/rs.3.rs-660094/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background
Hemodialysis patients are among high-risk groups for COVID-19. Africa is the continent with the lowest number of cases in the general population but we have little information about the disease burden in dialysis patients.

Objectives:
This study aimed to describe the seroprevalence of SARS-CoV-2 antibodies in the hemodialysis population of Senegal.

Patients and methods
We conducted a multicenter cross-sectional survey, between June and September 2020 involving 10 public dialysis units randomly selected in eight regions of Senegal. After seeking their consent, we included 303 patients aged ≥18 years and hemodialysis for ≥3 months. Clinical symptoms and biological parameters were collected from medical records. Patients’ blood samples were tested with Abbott SARS-CoV-2 Ig G assay using an Architect system. Statistical tests were performed with STATA 20.

Results
Seroprevalence of SARS-CoV-2 antibodies was 21.1% (95% CI= 16.7%-26.1%). We noticed a wide variability in SARS-CoV-2 seroprevalence between regions ranging from 5.6% to 51.7%. Among the 38 patients who underwent nasal swab testing, only six patients had a PCR-confirmed infection and all of them did seroconvert. Suggestive clinical symptoms were reported by 28.1% of seropositive patients and the majority of them presented asymptomatic disease. After multivariate analysis, a previous contact with a confirmed case and living in a high population density region were associated with the presence of SARS-CoV-2 antibodies.

Conclusion
This study presents to our knowledge the first seroprevalence data in African hemodialysis patients. Compared to data from other continents, we found a higher proportion of patients with SARS-CoV-2 antibodies but a lower lethality rate.

Introduction
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health issue since its description in December 2019 in China [1]. Pandemic was declared by WHO at the end of January 2020 as the disease spread to all continents and imposed perturbations in healthcare, socio-
economic and political systems [2, 3]. Patients with end-stage renal disease receiving dialysis treatment are very exposed to the SARS-CoV-2 during their frequent visits to healthcare facilities and immune induced by uremia. Moreover, available data identified them as among the highest risk groups for severe cases and death upon contracting COVID-19 [2]. Since the pandemic declaration, various strategies to reduce the risk of COVID-19 infection in patients receiving in-center hemodialysis have been rapidly implemented in many countries [3]. Despite these measures, high numbers of COVID-19 cases and related death have been continuously reported in the world. For unclear reasons, the African continent was less hit by the pandemic with lower incident cases and death in the general population [4] and patients with ESRD [5]. Among the most likely hypotheses to explain this African exception is the possible cross-immunity with other common pathogens, younger mean age, lower life expectancy, smaller pool of old people surviving and living with chronic non-communicable diseases [4]. However, given the majority of asymptomatic cases, the real burden of the COVID-19 pandemic might be underestimated in absence of a massive testing strategy (PCR or serology) in the population [6]. To our knowledge, seroprevalence data in African hemodialysis patients has not been reported yet. This study investigated the prevalence of SARS-CoV-2 serologic markers and their associated factors in a nationally representative cohort of hemodialysis patients in Senegal.

**Patients And Methods**

We performed a cross-sectional multicenter study between June and September 2020 involving 10 dialysis units randomly selected in eight regions of Senegal. Patients aged ≥ 18 years, on chronic hemodialysis for at least 3 months were included. Patients who did not give their consent and those with a diagnosis of acute kidney injury were excluded. For each patient, we collected past clinical symptoms during 3 months and dialysis parameters from medical records. We also collected information about previous positive PCR tests in patients who were presented symptoms or were in contact with a confirmed COVID-19 case. Following the national COVID-19 management protocol, only patients with suspected clinical symptoms were proposed to do nasal swab tests for RT-PCR. Biological parameters were obtained from blood samples collected before one mid-week dialysis session during routine laboratory check-ups of patients.

**SARS-CoV-2 Antibody Detection**

Patients’ samples were tested with the Healgen IgM/IgG One Step Rapid Test which measures separately the antibodies IgM and IgG. The test was run according to the manufacturer instructions. Into the test window, we added 5µl of serum and three drops of buffer provided in the kit. Then, results were read after 10 min (max 15 min) and only tests in which the control line changed its color were considered as valid. If a line was observed for IgM and/or IgG, the test was considered positive. The intensity of the color was not judged.

According to the manufacturer, the specificity evaluated on PCR-negative samples and was 100% for both IgM and IgG, while the sensitivity evaluated on COVID-19 cases was calculated at 87.9% for IgM and
97.2% for IgG. Li et al. have shown an overall testing sensitivity of 88.7% and 90.6% specificity [7]. We have also evaluated the testing kit and found a sensitivity of 76.26% and specificity of 98.48% for IgM and a sensitivity of 83.38% and specificity of 96.96% for IgG. In recovery patients, the IgG sensitivity was 98.1% and the specificity 96.96% (unpublished data).

The study protocol was submitted to and approved by the “Ethical Committee of Faculty of Medicine, Pharmacy and Odontostomatolgy” at University Cheikh Anta Diop, (Dakar, Senegal).

Statistical analyses were performed using STATA 20 and R. Continuous variables were described as mean (standard deviation) or median (interquartile range). Normally distributed variables were compared with t-test, and nonparametric data were compared with the Mann-Whitney test. Categorical variables were presented as percent and Fisher exact tests or chi-squared tests were used for proportional assessments. For all statistical tests, we accepted two-sided level of significance was set at \( p \leq 0.05 \).

**Results**

Out of 335 eligible hemodialysis patients, 303 were included in the study and had serologic testing for SARS-CoV-2 (Fig. 1). Sixty-four patients presented antibodies against the virus (seroprevalence of 21.1% with a 95% CI between 16.7% and 26.1%). About 95.3% of them had IgG antibodies. Table I presents socio-demographical characteristics and dialysis parameters of patients.

Seroprevalence of SARS-CoV-2 was comparable in men (24.3%) compared to women females (17.2%) \( (p = 0.13) \) and tended to be higher in patients older than 65 years even this was not statistically significant (Fig. 2).

Also, we found a remarkable variability in SARS-CoV-2 seroprevalence between regions ranging from 5.6–51.7%. Patients from dialysis centers in the three regions of Dakar, Diourbel, and Ziguinchor presented a higher rate of seroconversion compared to those who lived in the rest of the country (Fig. 3).

During the past three months, 38 patients underwent nasal swab testing but only six patients had a PCR-confirmed infection and all of them did seroconvert.

Of the 64 patients with SARS-CoV-2 antibodies, only 18 (28.1%) presented suggestive clinical symptoms. The majority of them had an asymptomatic disease and did not have any PCR testing. Patients with positive SARS-CoV-2 serology experienced significantly more respiratory symptoms and fever than those who were seronegative. Also, severe anemia and lymphopenia were more frequent among COVID-19 patients (see table II).

Serology tests were repeated 3 months later in 25 patients with SARS-CoV-2 antibodies and IgG persisted in 20 of them without evidence of new clinical symptoms.

At univariate analysis, a positive COVID-19 serologic test was associated with clinical symptoms, known contact with a confirmed COVID-19 case, and living area.
However, after multivariate logistic regression analysis, only the existence of the previous contact with a confirmed case and living a high population density region were associated with the presence of SARS-CoV-2 antibodies.

Among the infected patients, only six (1.9%) were admitted to intensive care units and three deaths due to COVID-19 were recorded during the study period (mortality rate and lethality rate of 0.9% and 4.6% respectively).

**Discussion**

In this nationwide survey of COVID-19 seroprevalence among hemodialysis patients in Senegal, we found that more than one patient in five presented specific antibodies by end of October 2020. Data from previous studies in hemodialysis cohorts reported variable but lower seroprevalences with 2.2% in Wuhan, China [8], 3.3% in France [9], 10.7% in the United Kingdom [10], 14.6% in Brescia, Italy [11], and from 3.5–27.2% in the USA [12]. In a recent review by Kooman JP, et al. the incidence of COVID-19 confirmed by RT-PCR among dialysis patients varied between 0.03% and 19.6% [3].

Unexpectedly our patients aged > 65 years showed the highest seroprevalence contrasting with publications where elders in dialysis showed a lower exposition to SARS-CoV-2 but a higher lethality rate [9, 12, 13, 14]. The age structure of the dialysis population in Africa is very different from developed countries where the majority of dialysis patients are 65 years old [9, 10, 11].

The existence of the previous contact with a COVID-19 case and population density were the strongest factors associated with a positive serology among hemodialysis patients. Regional disparities observed within the country have been also noticed in previous nationwide surveys [9, 12]. They could be explained by the intensity of virus circulation and promiscuity. The regions hosting two-thirds of infected patients were the most densely populated. In these settings, patients used to take crowded public transports to come to dialysis centers. The same hypothesis was evoked by Anand et al in a US nationwide comparative study which found that residents of neighborhoods with high population density presented a ten times higher risk of seropositivity compared with residents of lowest density areas [12]. Since the early pandemic, epidemiological studies suggested that SARS-CoV-2 basic reproduction number (R0) increases linearly with population density [15] and this was why clusters were observed in crowded and confined spaces, mass gatherings, and populous metropolitan areas [16, 17].

In contrast to the remarkable differences noted between Africa and the rest of the world regarding the extent of COVID-19 in the general population, we found among the hemodialysis subgroup a proportion of patients infected with SARS-CoV-2 which was comparable to data reported in other continents. Some authors suggested that the lower burden of COVID-19 in African countries could be explained by a majority of asymptomatic cases that were not diagnosed [18]. COVID-19 in our hemodialysis patients presented as an asymptomatic disease in 71.9% of cases. Similar to our findings, fever, cough, dyspnea, and fatigue are the most common symptoms described in patients with COVID-19 [3, 19] but digestive or cerebral manifestations can be more prominent in some cases [20].
Many studies using either PCR or serology tests had pointed out the predominance of asymptomatic forms in hemodialysis patients [12, 21] and underlined the paramount importance of preventive measures for all patients and staff inside dialysis centers. Testing strategies focusing on symptomatic cases only are known to underestimate the burden of the COVID-19 as it was demonstrated in the US population during the first wave of the pandemic that fewer than 10% of adults developed antibodies against SARS-CoV-2, and fewer than 10% of those were diagnosed [12]. Furthermore, African populations might develop a slightly different immune system response against the virus modulated by the multiple interactions with environmental factors and pathogens [22, 23].

Routine full blood count did not show any specific abnormalities in our patients with positive serology contrasting with data general population where one in four COVID-19 patients presented leukopenia (WBC < 4×10^9 cells/L) and lymphocytopenia (lymphocyte count < 1×10^9 cells/L) was found in 63.0% of them [13]. Albalate M, et al reported lymphopenia in almost half of the dialysis patients with confirmed COVID-19 [21]. Various hematologic features were reported in patients with COVID-19 but hyperleukocytosis, lymphocytopenia, and thrombocytopenia might be correlated with disease severity [24]. The absence of such hematologic perturbations in this study is concordant with the low COVID-19 related morbidity and mortality rates observed in our patients who rarely presented with severe forms of the disease requiring admission at intensive care units.

This mortality rate of less than 1% among Senegalese hemodialysis patients is following relatively fewer deaths reported in African populations since the first pandemic wave [4, 18]. However, emerging data suggest a more deadly second wave with a 40% increase in deaths in the continent since January 2021 [25]. Studies in other continents showed a mortality rate between 20% and 32.8% in hemodialysis patients with COVID-19 [25, 27, 28]. The younger age in our cohort was the main explanation for the lower number of deaths despite a higher incidence of COVID-19 cases.

In absence of seroprevalence data in the Senegalese general population, our findings in this representative nationwide hemodialysis cohort could serve as a good proxy to guide decisions of health authorities in the elaboration of an evidence-based strategy against COVID-19. Hemodialysis patients represent a good sentinel population in which to study the evolution of the current pandemic. Because we performed a serological test using blood samples collected as part of routine medical care, our results might not be influenced by possible selection bias compared to other previous studies that used nasal swab RT-PCR tests usually reserved for symptomatic patients.

Thus, these data in hemodialysis patients present a great epidemiological interest because it can be linked to community-level data to enable evaluation and quantification of differences in SARS-CoV-2 prevalence across socio-demographic and geographical strata, and thus develop efficient strategies targeting the highest-risk groups and areas.

Recent immunological studies demonstrated that patients with mild COVID-19 forms might develop multipotent SARS-CoV-2-specific immune memory response and IgG antibodies against spike protein could persist after recovery at least for three to six months [29, 30]. By demonstrating that many
hemodialysis patients had already evidence of exposure and developed an immune response to SARS-CoV-2, this study opens prospects for future vaccination strategies in this specific group. The rationale of mass vaccination without excluding recovered patients with enough SARS-CoV-2 Ig G is yet to be demonstrated and benefits should be balanced with possible side effects and costs particularly in hemodialysis patients [30].

**Limits**

Although we used a large and representative sample of dialysis patients in Senegal, our study presents some limits. First, the antibodies IgM and IgG are detected day 3–7 days after a person is infected by SARS-CoV-2 which suggests the serology test used may miss early infected people. Secondly, the retrospective collection of clinical symptoms and routine biological analysis could induce some recall bias when information was not written in the patient medical record. Also, we did not have some socio-demographical parameters like employment status, income level, living space, household size, and type of transportation from house to the dialysis center that could influence patient’s risk of contamination. However, the current results in this sub-group of dialysis patients might not reflect the true estimates in the general population. These results probably underestimate overall seroprevalence because dialysis patients usually face restrictions in their socio-professional activities due to their condition and maybe less in contact with the general population [31, 32]. Furthermore, data from hepatitis B post-immunization studies had demonstrated that compared to the general population, patients receiving dialysis might have a weaker immune response to viral antigen and thus be less likely to develop protective antibodies [33].

Finally, the early release and implementation of national guidelines for prevention and control of COVID-19 cases in dialysis facilities might have reduced the risk of in-center infections among patients and health workers.

**Conclusion**

This study showed that despite a high seroprevalence of SARS-CoV-2 antibodies in Senegalese hemodialysis patients the majority of them presented with asymptomatic disease. Some variations were noticed between age groups and geographical areas. Also, COVID-19 was associated with a low hospitalization and fatality rate in hemodialysis patients. These findings could help inform detection and management strategies that can gain effectiveness by combining both nasal swab RT-PCR and antibody screening and by sensitizing more dialysis patients and their neighborhoods on the COVID-19 preventive measures. Furthermore, in this context of a high number of individuals who already developed SARS-CoV-2 antibodies, the cost-effectiveness and risk-benefit of current vaccination strategies targeting vulnerable populations such as dialysis patients should be discussed.

**Declarations**
The authors declare that they have no financial disclosures related to this work.

**Ethics approval and consent to participate**

The study protocol was submitted to and approved by the “Ethical Committee of Faculty of Medicine, Pharmacy and Odontostomatolgy” at University Cheikh Anta Diop, Dakar.

Oral consent was from patients because majority of them were not literate.

**Consent for publication**

Not Applicable

**Availability of data and material**

Yes. Dr Moustapha Mbow, Laboratoire d'Immunologie, IRESSEF Diamniadio, Dakar, Senegal. Contact: moustapha.mbow@ucad.edu.sn

**Competing interests**

“Nothing to declare”

**Funding**

Fund O-COVID-19 from Senegalese Ministry of High Education and Scientific Research

**Authors’ contributions**

“S.M.S., M.Mb. and Y.D.P. designed the study and wrote protocol. S.M.S., M. Mb, YD, A.K., M.S., P.N., M.C., M.S.D., and I.D. contributed to data collection and analysis. M.Mb and Y.D.P performed biological tests. S.M.S and M.Mb. wrote the main manuscript text and prepared figures and tables. All authors reviewed the manuscript.”

**Acknowledgements:**

The authors are grateful to Dr Mamadou A Ba, Ms Fatou SECK, and all staff of dialysis units at HMO, HOGIP, Kaolack, Louga, Saint-Louis, Thies, Tamba, Ziguinchor, Touba.

-African Excellency Research Center for Health and Environment (CEA-AGIR)

-International Research Laboratory “Environment-Health-Society” (IRL-3189).

**References**

1. Whitworth J. COVID-19: a fast evolving pandemic. Trans. R Soc Trop Med Hyg. **114**(4), 241–8 (2020). doi: 10.1093/trstmh/traa025.
2. Alberici, F., Delbarba, E., Manenti, C., Econimo, L., Valerio, F., Pola, A., et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. *Kidney. Int.* **98**(1), 20–6 (2020). doi: 10.1016/j.kint.2020.04.030.

3. Kooman, J. P., van der Sande, F. M. COVID-19 in ESRD and Acute Kidney Injury. *Blood. Purif.* **50**, 610–20 (2020). doi: 10.1159/000513214.

4. Lawal, Y. Africa’s low COVID-19 mortality rate: A paradox? *Inter. J Infect Dis.* **102**, 118–22 (2021). doi: 10.1016/j.ijid.2020.10.038.

5. Elsayed, H. M., Wadee, S., Zaki, M. S., Were, A. J. O., Ashuntantang, G. E., Bamgboye, E. L., et al. Guidelines for the prevention, detection and management of the renal complications of COVID-19 in Africa. *African. J. Nephrol.* **23**(1), 109 – 26 (2020). doi: https://doi.org/10.21804/23-1-4097.

6. Koopmans, M., Haagmans, B. Assessing the extent of SARS-CoV-2 circulation through serological studies. *Nat. Med.* **26**(8), 1171-2 (2020). doi: 10.1038/s41591-020-1018-x.

7. Li, Z., Yi, Y., Luo, X., Xiong, N., Liu, Y., Li, S., et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *J. Med Virol.* **92**(9), 1518–24 (2020). doi: 10.1002/jmv.25727.

8. Xiong, F., Tang, H., Liu, L., Tu, C., Tian, J. B., Lei, C. T., et al. Clinical characteristics of and medical interventions for COVID-19 in hemodialysis patients in Wuhan, China. *J. Am Soc Nephrol.* **31**(7), 1387–97 (2020). doi: 10.1681/ASN.2020030354.

9. Couchoud. C., Bayer, F., Ayav, C., Béchade, C., Brunet, P., Chantrel, F., et al. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients. *Kidney. Int.* **98**(6), 1519–29 (2020). doi: 10.1016/j.kint.2020.07.042.

10. UK Renal Registry COVID-19 surveillance report for renal centres in the UK. Vol 20202020. https://renal.org/covid-19/data/. (Accessed October 23, 2020).

11. Alberici, F., Delbarba, E., Manenti, C., Econimo, L., Valerio, F., Pola, A., et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARSCoV-2 infection. *Kidney. Int.* **98**(1), 20 – 6 (2020). doi: 10.1016/j.kint.2020.04.030.

12. Anand S, Montez-Rath M, Han J, Bozeman J, Kerschmann R, Beyer P, et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. *Lancet.* **396**(10259), 1335-44 (2020). doi: 10.1016/S0140-6736(20)32009-2.

13. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. *Lancet.* **395**(10223), 497–506 (2020). doi: 10.1016/S0140-6736(20)30183-5.

14. Stringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet.* **396**(10247), 313-9 (2020). doi: 10.1016/S0140-6736(20)31304-0.

15. Rocklöv, J., Sjödin, H. High population densities catalyse the spread of COVID-19. *J. Travel Med.* **27**(3), taaa038 (2020). doi: 10.1093/jtm/taaa038.
16. Bialek, S., Bowen, V., Chow, N., Curns, A., Gierke, R. Hall., et al. Geographic differences in COVID-19 cases, deaths, and incidence—United States, February 12-April 7, 2020. MMWR Morb Mortal Wkly Rep. 69(15), 465 – 71 (2020). doi: 10.15585/mmwr.mm6915e4.

17. Baqui, P., Bica, I., Marra, V., Ercole, A., van der Schaar, M. Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study. Lancet. Glob Health. 8(8), e1018-26 (2020). doi: 10.1016/S2214-109X(20)30285-0.

18. Maoujoud, O., Ahid, S. The Coronavirus Disease 2019 (COVID-19) Pandemic in Africa: What Can We Expect? Value Health Reg Issues. 22, 35 (2020). doi: 10.1016/j.vhri.2020.05.001.

19. Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl J Med. 382(18), 1708-20 (2020). doi: 10.1056/NEJMoa2002032.

20. Gupta, A., Madhavan, M. V., Landry, D. W. Extrapulmonary manifestations of COVID-19. Nat Med. 26(7), 1017-32 (2020). doi: 10.1038/s41591-020-0968-3.

21. Albalate, M., Arribas, P., Torres, E., Cintra, M., Alcázar, R., Puerta, M., et al. High prevalence of asymptomatic COVID-19 in hemodialysis. Daily learning during first month of COVID-19 pandemic. Nefrologia. 40(3), 279–86 (2020). doi: 10.1016/j.nefro.2020.04.005.

22. Yatsunenko, T., Rey, F. E., Manary, M. J.,Trehan, I., Dominguez-Bello, M. G., Contreras, M., et al. Human gut microbiome viewed across age and geography. Nature. 486(7402), 222–7 (2012). doi: 10.1038/nature11053.

23. Brodin, P., Jojic, V., Gao, T., Bhattacharya, S., Angel, C. J., Furman, D., et al. Variation in the human immune system is largely driven by non-heritable influences. Cell. 160, 37–47. doi: 10.1016/j.cell.2014.12.020.

24. Słomka, A., Kowalewski, M., Zekanowska, E. Coronavirus Disease 2019 (COVID–19): A Short Review on Hematological Manifestations. Pathogens. 9(6), 493 (2020). doi: 10.3390/pathogens9060493.

25. World Health Organization – Regional Office for Africa. https://www.afro.who.int/news/rising-mortality-africa-marks-one-year-covid-19. (Accessed February 25, 2021)

26. Corbett, R. W., Blakey, S., Nitsch, D., Loucaidou, M., McLean, A., Duncan, N., et al. Epidemiology of COVID-19 in an Urban Dialysis Center. J. Am Soc Nephrol. 31(8), 1815–23. doi: 10.1681/ASN.2020040534.

27. Verma, A., Patel, A. B., Tio, M. C., Waikar, S. S. Caring for Dialysis Patients in a Time of COVID-19. Kidney Med. 2, (6) 787 – 92 (2020). doi: 10.1016/j.xkme.2020.07.006.

28. Quintaliani, G., Reboldi, G., Di Napoli, A., Nordio, M., Limido, A., Aucella, F., et al. Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology. J. Nephrol. 33, (4) 725 – 36 (2020). doi: 10.1007/s40620-020-00794-1.

29. Rodda, L.B., Netland, J., Shehata, L., Pruner, K.B., Morawski, P.A., Thouvenel, C.D., et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell. 184(1), 169–83 (2021). e17. doi: 10.1016/j.cell.2020.11.029.
30. Sakhi, H., Dahmane, D., Attias, P., Kofman, T., Bouvier, M., Lapidus, N., et al. Kinetics of Anti–SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection. *J. Am Soc Nephrol.* **32**(5), 1033–6 (2021). doi: 10.1681/ASN.2020111618.

31. Yaya, K., Moustapha, C.M., Mohamed, S.S., Tall, L.A., Maria, F., Christian, H., et al. Quality of life of patients on peritoneal dialysis in dakar: a Senegalese single centre experience. *Open. J Nephrol.* **6**, 37–42 (2016). doi: http://dx.doi.org/10.4236/ojneph.2016.62005.

32. Bao, Y., Dalrymple, L., Chertow, G. M., Kaysen, G. A., Johansen, K. L. Frailty, dialysis initiation, and mortality in end-stage renal disease. *Arch. Intern. Med.* **172**, 1071–7 (2012). doi: 10.1001/archinternmed.2012.3020.

33. Edey, M., Barraclough, K., Johnson, D. W. Review article: hepatitis B and dialysis. *Nephrology (Carlton).* **15**, 137–45 (2010). doi: 10.1111/j.1440-1797.2009.01268.x.

### Tables

Due to technical limitations, table 1,2,3 is only available as a download in the Supplemental Files section.

### Figures

![Figure 1](image)
Figure 2

Prevalence of SARS-CoV2 antibodies across age groups
Figure 3

Geographical distribution of SARS-CoV2 antibodies

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Table1.jpg
- Table2.jpg
- Table3.jpg